Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Lymphoid 1CNS 1

Conditions

Solitary Fibrous Tumors 1Sarcoma 1Neoplasm Metastasis 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Granuloma, Plasma Cell 1Glioma 1Glioblastoma 1

Interventions

Cyclophosphamide 5Brentuximab Vedotin 5Vincristine 4Rituximab 4Peripheral Blood Stem Cell Transplantation 4Ifosfamide 4Etoposide 4Doxorubicin 4Carboplatin 4romidepsin 3fludarabine phosphate 3brigatinib 3Prednisone 3Lenalidomide 3Everolimus 310-propargyl-10-deazaaminopterin 3pembrolizumab 2indolepropanol phosphate 2Whole-Body Irradiation 2Vorinostat 2Mycophenolic Acid 2Microarray Analysis 2Immunohistochemistry 2Gene Expression Profiling 2Cytarabine 2Cyclosporine 2Clofarabine 2Bendamustine Hydrochloride 2veliparib 1repotrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, Large-Cell, Anaplastic × Capsules × Clear all
NCT04094610 2025-11-19

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
75 enrolled
CNSLymphoidPlasma cellSarcoma

Glioblastoma, Glioma, Granuloma, Plasma Cell, Lymphoma, Neoplasm Metastasis, Sarcoma, Lymphoma, Large-Cell, Anaplastic, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡